drospirenone: Clinical Trials

9 trials of drospirenone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 1 recruiting, 1 terminated. 9 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 29Completed 7, Recruiting 1, Terminated 1
Phase 12Completed 1, Recruiting 1
Phase 31Completed 1

Follow drospirenone: new trials by email Literature Review of drospirenone trials Research Report on drospirenone

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study
Drospirenone - Contraception
Phase 1 / Phase 2RecruitingChulalongkorn University162024-04-182026-03-19
Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder
Yaz, Placebo - Premenstrual Dysphoric Disorder, Bipolar Disorder
Phase 2CompletedSt. Joseph's Healthcare Hamilton172023-02-032024-09-23
E4/DRSP Ovarian Function Inhibition Study
15 mg E4/3 mg DRSP, 20 mcg EE/3 mg DRSP - Prevention of Pregnancy
Phase 2CompletedEstetra822017-02-072023-05-03
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
15 mg E4/3 mg DRSP, 30 mcg EE/150 mcg LNG, 20 mcg EE/3 mg DRSP - Contraception, Liver Metabolism
Phase 1 / Phase 2CompletedEstetra1012016-09-012018-02-05
A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS
drospirenone and ethinyl estradiol (YAZ), Placebo - Hidradenitis Suppurativa
Phase 2TerminatedMassachusetts General Hospital42008-10-012014-02-10
Cycle Control and Safety of E2-DRSP
E2/DRSP (BAY 86-4891) dose 1 (SH T04984E), E2/DRSP (BAY 86-4891) dose 2 (80458739), E2/DRSP (BAY 86-4891) dose 3 (80458755) - Contraceptive, Oral, Hormonal
Phase 2CompletedBayer6352008-03-012015-04-23
A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles
BAY86-4891 (Estradiol / Drospirenone) - Contraception
Phase 2CompletedBayer1032008-02-012014-12-02
Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea
DRSP 3 mg/EE 20 µg (13 cycles), DRSP 3 mg/EE 30 µg (6 cycles) - Dysmenorrhea
Phase 2 / Phase 3CompletedBayer4202007-02-012013-01-24
Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Yasminelle (SH T 00186 D) - Contraceptives, Oral
Phase 2CompletedBayer1052004-05-012014-10-13

Conditions studied

Bipolar Disorder (1)  ·  Dysmenorrhea (1)  ·  Hidradenitis Suppurativa (1)  ·  Obesity (1)  ·  Premenstrual Dysphoric Disorder (1)

Sponsors

Bayer (4)  ·  Estetra (2)  ·  Chulalongkorn University (1)  ·  Massachusetts General Hospital (1)  ·  St. Joseph's Healthcare Hamilton (1)

Countries

Netherlands (3)  ·  Germany (2)  ·  Canada (1)  ·  Japan (1)  ·  Thailand (1)  ·  United States (1)

Top investigators

Christine Klipping (2)  ·  Alexandra B Kimball, MD, MPH (1)  ·  Benicio N Frey, MD, MSc,PhD (1)  ·  Punyawee Utaipatanacheep (1)

Results publications

PMID 10560680, PMID 11245554, PMID 11433905, PMID 12841897, PMID 19461456, PMID 21721590, PMID 2449395, PMID 26232513, PMID 27467196, PMID 28433989, PMID 29634911, PMID 30347490, PMID 31493139, PMID 31758920, PMID 32202076, PMID 32312141, PMID 33008401, PMID 33547015, PMID 3450848, PMID 36103980, PMID 36316023, PMID 37365881, PMID 37523477, PMID 37544572, PMID 7068318, PMID 7500749, PMID 7500750, PMID 9673838

NIH funding

2016 (2)